Isolated limb perfusion with high-dose tumor necrosis factor and melphalan for Kaposi sarcoma

Archives of Surgery

Volumn 134, Issue 2, 1999, Pages 177-180

  Lev Chelouche, Dina ^a   Abu Abeid, Subhi ^a   Merimsky, Ofer ^a   Isakov, Josephine ^a   Kollander, Yoram ^a   Meller, Isaac ^a   Klausner, Joseph M ^a   Gutman, Mordechai ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYTOTOXIC AGENT; DAUNORUBICIN; INTERFERON; MELPHALAN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; VINCA ALKALOID;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; HUMAN; HYPERTHERMIC THERAPY; INTRAARTERIAL DRUG ADMINISTRATION; KAPOSI SARCOMA; LIMB AMPUTATION; LIMB SALVAGE; MALE; PRIORITY JOURNAL; SKIN BIOPSY; SKIN CARCINOGENESIS; TREATMENT INDICATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; FOLLOW-UP STUDIES; HUMANS; LEG; MALE; MELPHALAN; MIDDLE AGED; PERFUSION; SARCOMA, KAPOSI; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033027359     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.134.2.177     Document Type: Article

References (35)

1. Cox FH, Helwig EB. Kaposi's sarcoma. Cancer. 1959;12:289-298.
2. Zatari B, Anhalt TS. Kaposi's saroma. Semin Dermatol. 1984;3:69-77.
3. Tappero JW, Conant MA, Wolfe SF, Berger TG. Kaposi's sarcoma: epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Dermatol. 1993;28:371-395.
4. Krown SE, Myskowski PL, Paredes J. Kaposi's sarcoma. Med Clin North Am. 1992;76:235-252.
5. Martin RW, Hood AF, Farmer ER. Kaposi's sarcoma. Medicine. 1993;72:245-261.
6. Northfeld DW. Treatment of Kaposi's sarcoma: current guidelines and future prospectives. Drugs. 1994;48:569-582.
7. Rybojod M, Borradai L, Verola O, Zeller J, Puissant A, Morel P. Non-AIDS associated Kaposi's sarcoma (classical and endemic African types): treatment with low doses of recombinant interferon-alpha. J Invest Dermatol. 1990;95:1765-1795.
8. Tur E, Brenner S. Treatment of Kaposi's sarcoma. Arch Dermatol. 1996;132:327-331.
9. El Akkad S, Bull CA, El-Senaissi MA, Griffin JT, Anner M. Kaposi's sarcoma and its management by radiotherapy. Arch Dermatol. 1986;122:1396-1399.
10. Cooper JS, Sacco J, Newall Y. The duration of local control of classic (non-AIDS-associated) Kaposi's sarcoma by radiotherapy. J Am Acad Dermatol. 1988;19:59-66.
11. Lienard D, Ewelenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992;10:52-60.
12. Eggermont AMM, Schraffordt-Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: the cumulative multicenter European experience. Ann Surg. 1996;6:756-765.
13. Gutman M, Inbar M, Lev-Shlush D, et al. High-dose tumor necrosis factor-α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in >90% response rate and limb preservation. Cancer. 1997;79:1129-1137.
14. Wieberdink J, Benckhuysen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18:905-910.
15. Haranak K, Satomi N, Sukari A. Antitumor activity of murine tumor necrosis factor against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer. 1984;34:263-267.
16. Asher AL, Mule JY, Reichert CM, Shiloni E, Rosenberg SA. Studies of the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol. 1987;138:963-974.
17. Wantanabe N, Niitsu Y, Umeno H, et al. Toxic effect of TNF on tumor vasculature in mice. Cancer Res. 1988;49:2179-2183.
18. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986;163:740-745.
19. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with actions of interleukin-1. Proc Natl Acad Sci U S A. 1986;83:4533-4537.
20. Klein MB, Pereira FA, Kantor I. Kaposi's sarcoma complicating systemic lupus erythematosus treated with immunosuppression. Arch Dermatol. 1974;110:602-604.
21. Penn I. Kaposi's sarcoma in organ transplant recipients: report of 20 cases. Transplantation. 1979;27:8-11.
22. Kapadia SB, Krause JR. Kaposi's sarcoma after long-term alkylating agent therapy for multiple myeloma. South Med J. 1977;70:1011-1013.
23. Beutler B, Cerami A. Tumor necrosis, cachexia, shock and inflammation: a common mediator. Ann Rev Biochem. 1988;57:505-518.
24. Quinn TD, Polk HC Jr, Edwards MJ. Hyperthermic isolated limb perfusion increases circulating levels of inflammatory cytokines. Cancer Immunol Immunother. 1995;40:272-275.
25. Tracey KY, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science. 1986;234:470-473.
26. Kahn JO, Kaplan LD, Volberding PA, et al. Intralesional recombinant tumor necrosis factor-α for AIDS-associated Kaposi's sarcoma: a randomized, doubleblind trial. J AIDS. 1989;2:217-223.
27. Krosnick JA, Mule JJ, McIntosh JK, Rosenberg SA. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo. Cancer Res. 1989;49:3729-3733.
28. Alonso K, Potiggia P, Nardi C, Sabato A, Cuppone CF. Systemic hyperthermia in the treatment of HIV-related Kaposi's sarcoma: a phase I study. Biomed Pharmacother. 1992;46:21-24.
29. Alosno K, Ponfiggia P, Sabato A, et al. Systemic hyperthermia in the treatment of HIV-related disseminated Kaposi's sarcoma: long-term follow-up of patient with low-flow extracorporeal perfusion hyperthermia. Am J Clin Oncol. 1994;17:353-359.
30. Robbins HJ, d'Oleire F, Kutz M, et al. Cytotoxic interactions of tumor necrosis factor, melphalan and 41.8°C hyperthermia. Cancer Lett. 1995;89:55-62.
31. Brambilla L, Boneschi IV, Beretta G, Finzi AF. Chemotherapeutic approach to Kaposi's sarcoma. In: Cerimele D, ed. Kaposi's Sarcoma. New York, NY: Spectrum; 1985:137-148.
32. Real FX, Herbert HF, Krown SE. Kaposi's sarcoma and the acquired immune deficiency syndrome: treatment with high and low doses of recombinant leukocyle A interferon. J Clin Oncol. 1986;4:544-551.
33. Krown SE, Real FX, Vadhan-Ray S, et al. Kaposi's sarcoma and the acquired immune deficiency syndrome: treatment with recombinant interferon alpha and analysis of prognostic factors. Cancer. 1986;57:1662-1665.
34. Gottlieb JJ, Washenik K, Chachoua A, et al. Treatment of classic Kaposi's sarcoma with liposomal encapsulated doxorubicin. Lancet. 1977;350:1363-1364.
35. Fournier S, Dupont B, Gialoux G, et al. Efficacy and tolerance of liposomal daunorubicin in Kaposi sarcoma associated with human immunodeficiency virus infection. Arch Dermatol. 1997;133:918-919.